免疫检查点抑制剂用于治疗晚期食管鳞状细胞癌的一线治疗。
Immune checkpoint inhibitors for first-line treatment of advanced esophageal squamous cell carcinoma.
机构信息
Medical Oncology Department, Hospital Universitario de Navarra, Translational Medical Oncology Investigational Group, Navarrabiomed - IdiSNA, C/ Irunlarrea 3, 35008 Pamplona, Spain.
Medical Oncology Department, Hospital Clínico Universitario de Valencia, INCLIVA, Valencia, Spain.
出版信息
Med. 2024 Sep 13;5(9):1038-1040. doi: 10.1016/j.medj.2024.05.016.
Immunotherapy has revolutionized the treatment landscape of esophageal squamous cell carcinoma. He et al. present the final results of the randomized phase 3 ESCORT-1st trial, confirming positive survival outcomes when adding the anti-PD1 inhibitor camrelizumab to first-line chemotherapy treatment in Chinese patients with esophageal squamous cell cancer..
免疫疗法已经彻底改变了食管鳞癌的治疗格局。何教授等人报告了随机 3 期 ESCORT-1st 试验的最终结果，证实了在一线化疗治疗中添加抗 PD1 抑制剂卡瑞利珠单抗可以为中国食管鳞癌患者带来阳性生存获益。
Zotero 插件